Apatinib mesylate in the treatment of advanced triple-negative breast cancer

This review examines the role of apatinib in treating TNBC and explores its potential mechanisms when combined with chemotherapeutic agents and ICIs for advanced TNBC in the era of immunotherapy.

Authors

Publication Details

Journal
Oncology Research and Treatment
Published
2026-02-17
DOI
https://doi.org/10.1159/000551064
Primary Topic
Cancer Treatment and Pharmacology
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Apatinib mesylate in the treatment of advanced triple-negative breast cancer

Xijia Huang, Weiwei Huang, Fan Wu, Hao Zeng et al.
Oncology Research and Treatment
Cancer Treatment and Pharmacology
article

Apatinib mesylate in the treatment of advanced triple-negative breast cancer

Xijia Huang, Weiwei Huang, Fan Wu, Hao Zeng, Mulan Chen, Lili Wang, Jian Liu, Chao Chen
article en

Abstract

This review examines the role of apatinib in treating TNBC and explores its potential mechanisms when combined with chemotherapeutic agents and ICIs for advanced TNBC in the era of immunotherapy.

Oncology Research and Treatment
Good health and well-being
Openalex Percentile: Top 53%
Cancer Treatment and Pharmacology
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.